Cellotetraose | 9036-88-8

• 物质功能分类: 生物化工 - 糖类化合物 - 寡糖
• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Cellotetraose
• 英文别名: 2-[6-[4,5-dihydroxy-2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 9036-88-8
• 化学式: C₂₄H₄₂O₂₁
• 分子量: 666.6
• InChiKey: LUEWUZLMQUOBSB-UHFFFAOYSA-N

物化性质

• 碰撞截面：
  234.7 Ų [M+H-H2O]+ [CCS Type: DT, Method: stepped-field]

计算性质

• 辛醇/水分配系数(LogP)：
  -9
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  348
• 氢给体数：
  14
• 氢受体数：
  21

文献信息

• COMPOSITION OF A 5-HT2A SEROTONIN RECEPTOR MODULATOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Selvey Lee Alani

  公开号：US20110207791A1

  公开（公告）日：2011-08-25

  The present invention relates to certain compositions of a 5-HT 2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.

  本发明涉及一种5-HT2A 5-羟色胺受体调节剂的特定组合物及其制备方法。本文所披露的组合物可用于增加慢波睡眠、改善睡眠巩固性、改善睡眠维持和改善睡眠质量，用于治疗失眠和相关的睡眠障碍、睡眠障碍、睡眠障碍和非恢复性睡眠等。本文所披露的组合物还可用于治疗血小板聚集、冠状动脉疾病、心肌梗塞、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、图雷特综合症、躁狂障碍、有机或NOS精神病、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、糖尿病相关疾病和进行性多灶性白质脑病等。
• PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)UREA AND CRYSTALLINE FORMS RELATED THERETO
  申请人：Carlos Marlon

  公开号：US20110207790A1

  公开（公告）日：2011-08-25

  The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.

  本发明涉及用于制备1-[3-(4-溴-2-甲基-2H-吡唑-3-基)-4-甲氧基-苯基]-3-(2,4-二氟-苯基)-脲(化合物I)的有用过程和中间体，其晶体形式和溶剂化合物形式；以及由本文所述过程制备的1-[3-(4-溴-2-甲基-2H-吡唑-3-基)-4-甲氧基-苯基]-3-(2,4-二氟-苯基)-脲、其晶体形式和溶剂化合物形式的组合物。
• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Glucksmann Alexandra

  公开号：US20120202772A1

  公开（公告）日：2012-08-09

  Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.

  本文描述了与CDP-蛋白酶体抑制剂偶联物相关的方法和组合物。
• PROCESSES USEFUL FOR THE PREPARATION OF 1-[3-(4-BROMO-2-METHYL-2H-PYRAZOL-3-YL)-4-METHOXY-PHENYL]-3-(2,4-DIFLUORO-PHENYL)-UREA AND CRYSTALLINE FORMS RELATED THERETO
  申请人：Arena Pharmaceuticals

  公开号：US20150210648A1

  公开（公告）日：2015-07-30

  The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.

  本发明涉及用于制备1-[3-(4-溴-2-甲基-2H-吡唑-3-基)-4-甲氧基苯基]-3-(2,4-二氟苯基)脲(化合物I)的有用中间体和工艺，其晶体形式和溶剂化物形式；以及包括1-[3-(4-溴-2-甲基-2H-吡唑-3-基)-4-甲氧基苯基]-3-(2,4-二氟苯基)脲、晶体形式和溶剂化物形式的组合物，所述组合物是由本文所述的工艺制备的。
• Small molecule metabolites for the diagnosis of bacterial vaginosis and assessment of disease risk
  申请人：Fred Hutchinson Cancer Research Center

  公开号：US10690651B2

  公开（公告）日：2020-06-23

  The invention disclosed herein generally relates to methods and kits for diagnosing, assessing disease risk, treating, and preventing bacterial vaginosis (BV) and associated conditions. Additional embodiments include methods for developing metabolic profiles associated with increased disease risk, and developing new approaches to treat BV based on interrupting metabolic networks.

  本文公开的发明一般涉及诊断、评估疾病风险、治疗和预防细菌性阴道病（BV）及相关疾病的方法和试剂盒。其他实施方案包括开发与疾病风险增加相关的代谢图谱的方法，以及开发基于干扰代谢网络治疗 BV 的新方法。

表征谱图